3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 15 | 2022-10-26 | 2026-07-21 |
| Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 185 | 2019-11-18 | 2026-07-21 |
| Clinical Trial Ceftriaxone in Subjects With ALS ceftriaxone, placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Completed | Massachusetts General Hospital | 513 | 2006-07-01 | 2014-04-21 |
Amyotrophic Lateral Sclerosis (1)
Central Nervous System Diseases (1) · Metabolic Diseases (1) · Motor Neuron Disease (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Proteostasis Deficiencies (1) · Spinal Cord Diseases (1) · TDP-43 Proteinopathies (1)
Edaravone (2) · Ceftriaxone (1)
Shionogi (2) · Massachusetts General Hospital (1)
Canada (2) · Japan (2) · United States (2) · France (1) · Germany (1) · Italy (1)
PMID 23613806, PMID 25297012, PMID 28864675, PMID 36504406
U01NS049640 (1)